Abstract:Nowadays, risperidone is an atypical antipsychotic drug that has been increasingly used for treatment and maintenance therapy in schizophrenia. However, partially affected by genetic or environmental factors, there is significant difference in treatment outcomes among patients. In this study, we aimed to interpret the difference between good and poor responders treated with risperidone in both genetic and epigenetic levels in 288 mainland Chinese patients. We recruited a Henan cohort including 98 patients as initial discovery group and then confirmed our results in Shanghai cohort. In genetic studies, we found 10 candidate single-nucleotide polymorphisms (SNPs) and 2 rare variants in Henan cohort by next-generation sequencing of 100 risperidone-response-related genes. After replication in Shanghai cohort by massarray platform, ultimately, rs6706232 and rs4818 were significantly associated with risperidone response in the two cohort meta-analysis (P = 0.024 and 0.04, respectively). Besides, we also selected another reported 17 candidate SNPs associated with risperidone drug response to replicate in our mainland Chinese samples, while, we found no significant SNPs after Bonferroni correction. In epigenetic studies, we investigated the methylation status in promoters or gene-coding region of risperidone drug response-related genes including CYP3A4, CYP2D6, ABCB1, HTR2A, DRD2. Totally we found seven significant CpG sites in the meta-analysis with Bonferroni-corrected PCYP3A4_CpG-36 = 0.0014, PCYP3A4_ CpG-258 = 0.0013, PCYP3A4_ CpG-296 = 0.0014, PCYP3A4_ CpG-367:-372:-374 = 0.028, P-CYP2D6_CpG_193 = 0.012, P-CYP2D6_CpG_242: 244: 250 = 0.00076 and P-CYP2D6_CpG_284 = 0.034, respectively. As genetic and epigenetic factors may interactively affect drug response, we finally carried out a multivariant interaction analysis with multifactor dimensionality reduction and discovered a significant four-locus model (CYP3A4_CpG_-82:-86 + rs6280+rs1800497+rs6265, P = 0.038) affecting drug response. These findings could partially explain different risperidone response outcome in Chinese population in a systematic level.

A Pharmacogenomic Study Revealed an Association Between SLC6A4 and Risperidone-Induced Weight Gain in Chinese Han Population.

Genome-Wide Association Study Suggested Theptprdpolymorphisms Were Associated with Weight Gain Effects of Atypical Antipsychotic Medications

Association study of FTOgene polymorphism with weight gain associated with 4 week risperidone treatment

Association Study of Nrxn3 Polymorphisms with Schizophrenia and Risperidone-Induced Bodyweight Gain in Chinese Han Population

Dopamine Transporter Polymorphisms and Risperidone Response in Chinese Schizophrenia Patients: an Association Study.

A Pharmacogenomic Study on the Polymorphic Gene Response to Risperidone in Schizophrenia Patients.

Association of MTHFR C677T polymorphism with weight gain induced by risperidone in schizophrenia

Association of Dopamine Receptor D1 (DRD1) Polymorphisms with Risperidone Treatment Response in Chinese Schizophrenia Patients.

Combined Study of Genetic and Epigenetic Biomarker Risperidone Treatment Efficacy in Chinese Han Schizophrenia Patients

C677T Polymorphism in the MTHFR Gene is Associated with Risperidone-Induced Weight Gain in Schizophrenia.

A Pharmacogenetic Study of Risperidone on Chemokine (C–C Motif) Ligand 2 (CCL2) in Chinese Han Schizophrenia Patients

A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients.

[No Association of -1438G/A Polymorphism in Promoter Region of 5-HT2A Receptor Gene with Antipsychotic Agent-Induced Weight Gain].

Association Studies of Genomic Variants with Treatment Response to Risperidone, Clozapine, Quetiapine and Chlorpromazine in the Chinese Han Population

Association of <i>MTHFR</i> C677T Polymorphism With Antipsychotic-Induced Change of Weight and Metabolism Index

TOX and ADIPOQ Gene Polymorphisms Are Associated with Antipsychotic-Induced Weight Gain in Han Chinese

Genetic Variants in the BDNF Gene and Therapeutic Response to Risperidone in Schizophrenia Patients: a Pharmacogenetic Study

Association of A2BP1 Gene Polymorphism with Olanzapine Induced Bodyweight Gain

Association Between a Polymorphism of the HTR3A Gene and Therapeutic Response to Risperidone Treatment in Drug-Naive Chinese Schizophrenia Patients

Meta-Analysis of Genome Wide Association Studies Showed Polymorphisms on 2P16.1, 6P22.1 and 10Q24.32 Associated with Schizophrenia in Chinese Han Population

Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis.